TrialCompass™ TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT07143929

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing CAR-T for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 80 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

CAR-T (DRUG): autologous CD7-targeted CAR-T cells, single injection

Drugs / treatments
CAR-T
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

NCT07143929

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing CAR-T for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 80 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

CAR-T (DRUG): autologous CD7-targeted CAR-T cells, single injection

Drugs / treatments: CAR-T

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 18 patients

Primary endpoint: safety: Dose-limiting toxicity

Ages: 18 Years to 80 Years

Start date: 2025-08-18 | Est. completion: 2027-12-31

Locations

0 US sites · 1 total

Contact

Xiaodong Mo, phd | mxd453@163.com | 8610-88326002

Sponsor: Peking University People's Hospital (OTHER)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07143929

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.